Literature DB >> 28353276

Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.

Edoardo Monfrini1, Alessio Di Fonzo2.   

Abstract

The discovery of LRRK2 mutations as a cause of Parkinson's disease (PD), including the sporadic late-onset form, established the decisive role of genetics in the field of PD research. Among LRRK2 mutations, the G2019S, mostly lying in a haplotype originating from a common Middle Eastern ancestor, has been identified in different populations worldwide. The G2385R and R1628P variants represent validated risk factors for PD in Asian populations. Here, we describe in detail the origin, the present worldwide epidemiology, and the penetrance of LRRK2 mutations. Furthermore, this chapter aims to characterize other definitely/probably pathogenic mutations and risk variants of LRRK2. Finally, we provide some general guidelines for a LRRK2 genetic testing and counseling. In summary, LRRK2 discovery revolutionized the understanding of PD etiology and laid the foundation for a promising future of genetics in PD research.

Entities:  

Keywords:  Dardarin; Familial Parkinson’s disease; LRRK2; LRRK2 mutations; Leucine-rich repeat kinase 2; PARK8; Parkinson’s disease; Parkinson’s disease genetics

Mesh:

Substances:

Year:  2017        PMID: 28353276     DOI: 10.1007/978-3-319-49969-7_1

Source DB:  PubMed          Journal:  Adv Neurobiol


  16 in total

Review 1.  Genetics of Movement Disorders and the Practicing Clinician; Who and What to Test for?

Authors:  Alessio Di Fonzo; Edoardo Monfrini; Roberto Erro
Journal:  Curr Neurol Neurosci Rep       Date:  2018-05-23       Impact factor: 5.081

Review 2.  [Genetic risk variants in Parkinson's disease and other movement disorders].

Authors:  K Brockmann; K Lohmann
Journal:  Nervenarzt       Date:  2017-07       Impact factor: 1.214

3.  Slowing Parkinson's Disease Progression with Vaccination and Other Immunotherapies.

Authors:  Dhanya Vijayakumar; Joseph Jankovic
Journal:  CNS Drugs       Date:  2022-02-25       Impact factor: 5.749

4.  Parkinson's Disease Skin Fibroblasts Display Signature Alterations in Growth, Redox Homeostasis, Mitochondrial Function, and Autophagy.

Authors:  Joji M Y Teves; Vedanshi Bhargava; Konner R Kirwan; Mandi J Corenblum; Rebecca Justiniano; Georg T Wondrak; Annadurai Anandhan; Andrew J Flores; David A Schipper; Zain Khalpey; James E Sligh; Clara Curiel-Lewandrowski; Scott J Sherman; Lalitha Madhavan
Journal:  Front Neurosci       Date:  2018-01-12       Impact factor: 4.677

5.  LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons.

Authors:  Michael X Henderson; Chao Peng; John Q Trojanowski; Virginia M Y Lee
Journal:  Acta Neuropathol Commun       Date:  2018-05-31       Impact factor: 7.801

6.  Comprehensive Genomic Analysis Reveals the Prognostic Role of LRRK2 Copy-Number Variations in Human Malignancies.

Authors:  Gianluca Lopez; Giulia Lazzeri; Alessandra Rappa; Giuseppe Isimbaldi; Fulvia Milena Cribiù; Elena Guerini-Rocco; Stefano Ferrero; Valentina Vaira; Alessio Di Fonzo
Journal:  Genes (Basel)       Date:  2020-07-24       Impact factor: 4.096

7.  LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson's disease patients.

Authors:  Daniel Ysselstein; Maria Nguyen; Tiffany J Young; Alex Severino; Michael Schwake; Kalpana Merchant; Dimitri Krainc
Journal:  Nat Commun       Date:  2019-12-05       Impact factor: 14.919

8.  Ciliogenesis is Not Directly Regulated by LRRK2 Kinase Activity in Neurons.

Authors:  Hyejung Kim; Hyuna Sim; Joo-Eun Lee; Mi Kyoung Seo; Juhee Lim; Yeojin Bang; Daleum Nam; Seo-Young Lee; Sun-Ku Chung; Hyun Jin Choi; Sung Woo Park; Ilhong Son; Janghwan Kim; Wongi Seol
Journal:  Exp Neurobiol       Date:  2021-06-30       Impact factor: 3.261

9.  Structural analysis of the full-length human LRRK2.

Authors:  Alexander Myasnikov; Hanwen Zhu; Patricia Hixson; Boer Xie; Kaiwen Yu; Aaron Pitre; Junmin Peng; Ji Sun
Journal:  Cell       Date:  2021-06-08       Impact factor: 66.850

Review 10.  From Synaptic Dysfunction to Neuroprotective Strategies in Genetic Parkinson's Disease: Lessons From LRRK2.

Authors:  Andrea Mancini; Petra Mazzocchetti; Miriam Sciaccaluga; Alfredo Megaro; Laura Bellingacci; Dayne A Beccano-Kelly; Massimiliano Di Filippo; Alessandro Tozzi; Paolo Calabresi
Journal:  Front Cell Neurosci       Date:  2020-07-28       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.